Partial loss of MCU mitigates pathology in vivo across a diverse range of neurodegenerative disease models

Madeleine J. Twyning,Roberta Tufi,Thomas P. Gleeson,Kinga M. Kolodziej,Susanna Campesan,Ana Terriente-Felix,Lewis Collins,Federica De Lazzari,Flaviano Giorgini,Alexander J. Whitworth
DOI: https://doi.org/10.1016/j.celrep.2024.113681
IF: 8.8
2024-01-18
Cell Reports
Abstract:Twyning et al. show using a single in vivo platform that reducing mitochondrial calcium uptake via MCU or increasing efflux via NCLX is beneficial across a variety of different disease models. These findings underscore the pathogenic role of mitochondrial calcium in neurodegeneration and highlight its potential as a therapeutic target.
cell biology
What problem does this paper attempt to address?